WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406224
Description: RO314724 is a HDAC inhibitor. RO314724 is also a a reversible, tightly binding, MMP inhibitor with a Ki of 26 nm. Matrix metalloproteinases (MMPs) belong to the key enzymes of the proteolytic destruction of cartilage matrix during chronic rheumatic diseases. Ro314724 displayed MMP-proteoglycanase inhibitory activity both in vitro and ex vivo and proved to be not harmful to the morphology, viability and proteoglycan biosynthesis of bovine articular cartilage explants.
MedKoo Cat#: 406224
Chemical Formula: C19H33N3O7
Exact Mass: 415.23185
Molecular Weight: 415.48
Elemental Analysis: C, 54.93; H, 8.01; N, 10.11; O, 26.96
Synonym: RO314724; RO 314724; RO314724; Ro 31-4724; Ro31-4724; Ro-31-4724.
IUPAC/Chemical Name: (2S)-ethyl 2-((2S)-2-(2-(2-(hydroxyamino)-2-oxoacetyl)-4-methylpentanamido)-4-methylpentanamido)propanoate
InChi Key: SEOSLRNQJVROOM-HPNRGHHYSA-N
InChi Code: InChI=1S/C19H33N3O7/c1-7-29-19(27)12(6)20-17(25)14(9-11(4)5)21-16(24)13(8-10(2)3)15(23)18(26)22-28/h10-14,28H,7-9H2,1-6H3,(H,20,25)(H,21,24)(H,22,26)/t12-,13?,14-/m0/s1
SMILES Code: C[C@H](NC([C@@H](NC(C(C(C(NO)=O)=O)CC(C)C)=O)CC(C)C)=O)C(OCC)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 415.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Steinmeyer J, Daufeldt S, Taiwo YO. Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol. 1998 Jan 1;55(1):93-100. PubMed PMID: 9413935.
2: Steinmeyer J, Daufeldt S, Kalbhen DA. Effects of the hydroxamic acid derivate Ro 31-4724 on the metabolism and morphology of interleukin-1-treated cartilage explants. Pharmacology. 1997 Aug;55(2):95-108. PubMed PMID: 9323309.
3: Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol. 1994;89 Suppl 1:59-70. Review. PubMed PMID: 7945177.
4: Finch-Arietta M, Johnson W, Lusch L, Fotouhi N, Walsky R, Hanglow AC. Characterization of a tight-binding MMP-3 inhibitor using improved fluorescence spectroscopy techniques. Agents Actions. 1993;39 Spec No:C189-91. PubMed PMID: 8273564.
5: Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992 Nov 15;288 ( Pt 1):93-9. PubMed PMID: 1445285; PubMed Central PMCID: PMC1132084.
6: Nixon JS, Bottomley KM, Broadhurst MJ, Brown PA, Johnson WH, Lawton G, Marley J, Sedgwick AD, Wilkinson SE. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int J Tissue React. 1991;13(5):237-41. PubMed PMID: 1666894.